Literature DB >> 477469

[Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin].

I Klempa, U Schwedes, K H Usadel.   

Abstract

Somatostatin was prophylactically administered to 10 patients who had surgery for pancreatic diseases. The postoperative course uncomplicated with no increase in serum amylase levels. Bile induced acute pancreatitis in six beagles was prophylactically treated with somatostatin. The results demonstrate that SRIF not only inhibits basal but also pancreatic-induced blood amylase and enzyme activities in the dog. SRIF-treated animals were in good general condition compared with untreated controls, macroscopic and histologic aspects of the pancreas were significantly improved.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 477469

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  20 in total

1.  Does prophylactic octreotide benefit patients undergoing elective pancreatic resection?

Authors:  C J Yeo
Journal:  J Gastrointest Surg       Date:  1999 May-Jun       Impact factor: 3.452

2.  Anastomotic leakage in pancreatic surgery.

Authors:  Stefano Crippa; Roberto Salvia; Massimo Falconi; Giovanni Butturini; Luca Landoni; Claudio Bassi
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

3.  The Use of  Prophylactic Somatostatin Therapy Following Pancreaticoduodenectomy: A Meta-analysis of Randomised Controlled Trials.

Authors:  A Adiamah; Z Arif; F Berti; S Singh; N Laskar; D Gomez
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

4.  Prophylactic octreotide for pancreatoduodenectomy: more harm than good?

Authors:  Matthew T McMillan; John D Christein; Mark P Callery; Stephen W Behrman; Jeffrey A Drebin; Tara S Kent; Benjamin C Miller; Russell S Lewis; Charles M Vollmer
Journal:  HPB (Oxford)       Date:  2014-07-10       Impact factor: 3.647

5.  Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; P K Sauter; J Coleman; T A Sohn; K A Campbell; M A Choti
Journal:  Ann Surg       Date:  2000-09       Impact factor: 12.969

6.  Role of somatostatin in the prevention of pancreatic stump-related morbidity following elective pancreaticoduodenectomy in high-risk patients and elimination of surgeon-related factors: prospective, randomized, controlled trial.

Authors:  Yan-Shen Shan; Edgar D Sy; Pin-Wen Lin
Journal:  World J Surg       Date:  2003-05-13       Impact factor: 3.352

7.  Analysis of closure of the pancreatic remnant after distal pancreatic resection.

Authors:  U Lorenz; M Maier; U Steger; C Töpfer; A Thiede; S Timm
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

8.  Octreotide Does Not Prevent Pancreatic Fistula Following Pancreatoduodenectomy in Patients with Soft Pancreas and Non-dilated Duct: A Prospective Randomized Controlled Trial.

Authors:  Prakash Kurumboor; Kamalesh Nadothottam Palaniswami; K Pramil; Deepak George; Shaji Ponnambathayil; Deepak Varma; Sylesh Aikot
Journal:  J Gastrointest Surg       Date:  2015-08-25       Impact factor: 3.452

9.  Prospective randomized trial of the effect of octreotide on pancreatic juice output after pancreaticoduodenectomy in relation to histological diagnosis, duct size and leakage.

Authors:  Laureano Fernández-Cruz; Enrique Jiménez Chavarría; Pilar Taurà; Daniel Closa; Miguel-Angel López Boado; Joana Ferrer
Journal:  HPB (Oxford)       Date:  2012-11-19       Impact factor: 3.647

Review 10.  Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery.

Authors:  C Bassi; M Falconi; P Pederzoli
Journal:  Gut       Date:  1994       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.